Zaprovalna О. Ye., Tripolka S.А.

ASPIRIN-RESISTANCE AND APPLICATION OF NONSTEROID ANTIINFLAMMATORY PREPARATIONS IN CARDIOLOGIC PRACTICE

---

About the author:	Zaprovalna О. Ye., Tripolka S.А.
Heading	CLINICAL MEDICINE
Type of article	Научная статья
Annotation	Nonsteroid anti-inflammatory drugs (NSAIDs) are common cause side effects. This study describes the drug interactions of NSAIDs and low-dose acetylsalicylic acid (aspirin), especially of the use of these drugs in cardiovascular diseases. Assessment of absolute risk, including cardiovascular risk, should be necessarily taken into account in the appointment of NSAIDs. It is essential to reduce the negative effects of NSAIDs on the disease and reduce cardiovascular and other risks
Tags	nonsteroid anti-inflammatory drugs, acetylsalicylic acid, cardiovascular risk
Bibliography	Бабак О.Я.  Применение нестероидных противовопалительных средств в терапии / Бабак О.Я., Князькова И.А., Нестерцова И.И. // УТЖ – 2007. - №2. – С.2-11. Рудык Ю.С Нестероидные противовоспалительные препараты:  эффективность и переносимость / Рудык Ю.С., Пивовар С.Н. - Харьков, 2011. – 64 с. Каратеев А.Е Применение нестероидных противовоспалительных препаратов (клинические рекомендации) / Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. //Москва, ИМА–ПРЕСС, 2009. - 167 с. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов (клинические рекомендации) / Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. //. Москва, «Алмаз», 2006. -  88 с. Patrono C..  Antiplatelet Agents (Expert Consensus Document on the Use of)  ESC Clinical Practice Guidelines/  Patrono C., Bachmann F., Baigent C. // EHJ. - 2004. – Vol.25. – P.166-181 Кукес В.Г. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей./  Кукес В.Г., Остроумова О.Д. – Киев, 2004 – 112с. Patrono C. Феномен резистентности к антитромбоцитарным препаратам / Patrono C., Rocca // Практична ангіологія. – 2008. - № 1. – С.58-67. Eikelboom J. W.. Aspirin Resistance: A New Independent Predictor of Vascular Events? / Eikelboom J. W.. // J Am Coll Cardiol 2003. – Vol. 41 (6). P. 966–968. Gum PA. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease/ Gum PA, Kottke–Marchant K, Welsh PA, White J, Topol EJ.//J Am Coll Cardiol. -  2003. – Vol. 41. P961–965. Eikelboom J.W. Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid/ Eikelboom J.W., Hankey G.J. // Circulation. – 2008. – Vol. 118. – P.1705-1712. Muir A.R. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease /  Muir A.R., McMullin M.F., Patterson C., McKeown P.P. //Heart. -  2009. –Vol.95. – P.1225-1229 Dalen J.E. Aspirin Resistance: Is it Real? Is it Clinically Significant?/ Dalen J.E.  // The American Journal of Medicine.- 2007. - Vol.120.- P.1-4. Angiolillo DJ.  Advances in antiplatelet therapy: agents in clinical development /  Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. // Am. J. Cardiol.-2009.-V.103(3 Suppl).-P. 40A-51A. Krasopoulos G. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis / Krasopoulos G., Brister S.J. , Beattie W.S. et al. // BMJ.-2008.-V. 336.-P. 195-198. Brister S.J. Aspirin “resistance” and its impact on cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured / Brister S.J, Buchanan M.R.  // Heart. – 2009. – Vol. 95, N15. – P.1223-1224. Patrono C. Platelet-active drugs: the relationships among dose, effectiveness, and side effects /  Patrono C., Coller B., FitzGerald G.A., Hirsh J., Roth G. // Chest. -  2004. Vol. 126. P. 234S–264S. Eikelboom J.W. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events / Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. // Circulation. -  2002. – Vol. 105. P.1650–1655. Gum P.A. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease / Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J // J Amer Coll Cardiol. -  2003. - V. 41. – P 961–965. McAdam BF. Sys-temic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 / McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA// Proc Natl Acad Sci USA. -  1999. - Vol. 96. – P. 272-277. Andersohn F. Use of First- and Second-Generation Cyclooxygenase-2–Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction /  Andersohn F., Suissa S., Garbe E //  Circulation. -  2006. – Vol. 113. - P. 1950-1957. Chan A.T. Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events / Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Rimm E.B., Willett W.C., Fuchs C.S.// Circulation. -  2006. – Vol. 113. P. 000-000. www.circulationaha.org Грацианский Н.А. Падение рофекоксиба. Последует ли за ним падение всего класса ингибиторов циклооксигеназы-2. / Грацианский Н.А. // Консилиум -  2004. – Т.6, №12. – С. 918-925. McGettigan P. Cardiovascular risk and inhibition of cyclooxygenase/McGettigan P., Henry D. // JAMA. - 2006. – Vol. 296. - P. 1633–1644. Hippisley-Cox J. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis / Hippisley-Cox J., Coupland C. // BMJ. -  2005. Vol. 330. P. 1366. Le´vesque L.E. The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults/ Le´vesque L.E., Brophy J.M., Zhang B//  Ann Intern Med.-  2005. – Vol. 142. P. 481-489. Gislason G.H. Increased Mortality Related to Treatment with Selective Cyclo-Oxygenase-2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs after Acute Myocardial Infarction./ Gislason G.H., Jacobsen S., Buch P., Rasmussen J.N., Friberg J., Abildstrom S.Z., Torp-Pedersen C. // Abstracts, AHA scientific sessions 2005, abstract 1838. European Medicines Agency concludes action on COX-2 inhibitors. Press release. European Medicines Agency 27 June 2005. Do.Ref.EMEA/207766/2005. www.emea.eu.int Trelle S. Cardiovascular safety of non-steroid anti-inflammatory drugs: network meta-analysis / Trelle S., Rechenbach S., Wandel S. // BMJ. – 2011. – Vol. 342. – P. 70-86. Strand V. Are COX–2 inhibitors preferable to non–selective non–steroidal anti–inflammatory drugs in patients with risk of cardiovascular events taking low–dose aspirin? / Strand V. // Lancet. – 2007. – Vol. 22; 370(9605). – P. 2138–2151.  Singh G. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase–2 selective and some non–selective non–steroidal anti–inflammatory drugs / Singh G., Graham D., Wang H. // Ann Rheum Dis. -  2006. – Vol. 65 (Suppl. II). – P. 61. Ломакин Н.В. Ингибиторы циклооксигеназы и антитромбоцитарный эффект ацетилсалициловой кислоты. Селективный подход к противовоспалительным средствам в кардиологической практике. / Ломакин Н.В., Груздев А.К. // Кардиология. – 2011. - №7. – С.47-52. Каратеев А.Е. Как правильно использовать нестероидные противовоспалительные препараты./ А.Е. Каратеев // Русский Медицинский Журнал. – 2009. - том 17, № 21. – С. 9-15 Каратеев А.Е. Нестероидные противовоспалительные средства при лечении боли в терапевтической практике / А.Е. Каратеев //CONSILIUM MEDICUM UKRAINA. – 2010. - №16. - оn line.
Publication of the article	«World of Medicine and Biology» №2(33), 2012 year, 35-39 pages, index UDK 611.1-085.-212.3: 615.276